2 assets in Ureter Adenocarcinoma

Therapeutic assets addressing Ureter Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Ureter Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Ureter Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)